{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:27:12Z","timestamp":1794641232358,"version":"4.9.1"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2020,10,19]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oral corticosteroid use increases the risk of systemic adverse effects including osteoporosis, bone fractures, diabetes, ocular disorders and respiratory infections. We sought to understand if inhaled corticosteroid (ICS) use in asthma is also associated with increased risk of systemic effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MEDLINE and Embase databases were searched to identify studies that were designed to investigate ICS-related systemic adverse effects in people with asthma. Studies were grouped by outcome: bone mineral density (BMD), respiratory infection (pneumonia or mycobacterial infection), diabetes and ocular disorder (glaucoma or cataracts). Study information was extracted using the PICO checklist. Risk of bias was assessed using the Cochrane Risk of Bias tool (randomised controlled trials) and Risk of Bias In Non-randomised Studies of Interventions-I tool (observational studies). A narrative synthesis was carried out due to the low number of studies reporting each outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirteen studies met the inclusion criteria, 2 trials and 11 observational studies. Study numbers by outcome were: six BMD, six respiratory infections (four pneumonia, one tuberculosis (TB), one non-TB mycobacteria), one ocular disorder (cataracts) and no diabetes. BMD studies found conflicting results (three found loss of BMD and three found no loss), but were limited by study size, short follow-up and lack of generalisability. Studies addressing infection risk generally found positive associations but suffered from a lack of power, misclassification and selection bias. The one study which assessed ocular disorders found an increased risk of cataracts. Most studies were not able to fully adjust for known confounders, including oral corticosteroids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There is a paucity of studies assessing systemic adverse effects associated with ICS use in asthma. Those studies that have been carried out present conflicting findings and are limited by multiple biases and residual confounding. Further appropriately designed studies are needed to quantify the magnitude of the risk for ICS-related systemic effects in people with asthma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2020-000756","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T16:25:17Z","timestamp":1606926317000},"page":"e000756","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":59,"title":["Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review"],"prefix":"10.1136","volume":"7","author":[{"given":"Roshni","family":"Patel","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumrah A","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Centre for Primary Care and Public Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe I","family":"Bloom","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"2025083110401699000_7.1.e000756.1","unstructured":"CDC . Asthma surveillance data. Available: https:\/\/www.cdc.gov\/asthma\/asthmadata.htm"},{"key":"2025083110401699000_7.1.e000756.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02130-2018"},{"key":"2025083110401699000_7.1.e000756.3","unstructured":"Global strategy for asthma management and prevention (2015 update)."},{"key":"2025083110401699000_7.1.e000756.4","unstructured":"British Thoracic Society . BTS\/SIGN British guideline on the management of asthma, 2019."},{"key":"2025083110401699000_7.1.e000756.5","unstructured":"Asthma | guidance and guidelines | NICE."},{"key":"2025083110401699000_7.1.e000756.6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1183\/09031936.04.00046704","article-title":"Meta-Analysis on dose-response relationship of inhaled steroids must be done in homogenous asthma populations","volume":"24","author":"Ingelf","year":"2004","journal-title":"Eur Respir J"},{"key":"2025083110401699000_7.1.e000756.7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.anai.2020.04.006","article-title":"Relative efficacy and safety of inhaled corticosteroids in patients with asthma: systematic review and network meta-analysis","volume":"125","author":"Chipps","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025083110401699000_7.1.e000756.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7307.253"},{"key":"2025083110401699000_7.1.e000756.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003145","article-title":"Health and cost impact of stepping down asthma medication for UK patients, 2001-2017: a population-based observational study","volume":"17","author":"Bloom","year":"2020","journal-title":"PLoS Med"},{"key":"2025083110401699000_7.1.e000756.10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110401699000_7.1.e000756.11","doi-asserted-by":"crossref","first-page":"1901147","DOI":"10.1183\/13993003.01147-2019","article-title":"Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma","volume":"55","author":"Maijers","year":"2020","journal-title":"Eur Respir J"},{"key":"2025083110401699000_7.1.e000756.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-213974"},{"key":"2025083110401699000_7.1.e000756.13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaip.2018.01.025","article-title":"Inhaled corticosteroids safety and adverse effects in patients with asthma","volume":"6","author":"Heffler","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083110401699000_7.1.e000756.14","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.9.941"},{"key":"2025083110401699000_7.1.e000756.15","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/jc.2015-1218","article-title":"Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis","volume":"100","author":"Broersen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025083110401699000_7.1.e000756.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"2025083110401699000_7.1.e000756.17","doi-asserted-by":"publisher","DOI":"10.4065\/79.4.458"},{"key":"2025083110401699000_7.1.e000756.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa002304"},{"key":"2025083110401699000_7.1.e000756.19","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.4.272"},{"key":"2025083110401699000_7.1.e000756.20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jocd.2005.11.005","article-title":"Inhaled steroids do not decrease bone mineral density but increase risk of fractures: data from the GIUMO Study Group","volume":"9","author":"Sosa","year":"2006","journal-title":"J Clin Densitom"},{"key":"2025083110401699000_7.1.e000756.21","doi-asserted-by":"publisher","DOI":"10.1002\/pds.941"},{"key":"2025083110401699000_7.1.e000756.22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2332\/allergolint.10-OA-0276","article-title":"Assessment of bone status in inhaled corticosteroid user asthmatic patients with an ultrasound measurement method","volume":"60","author":"Sasagawa","year":"2011","journal-title":"Allergol Int"},{"key":"2025083110401699000_7.1.e000756.23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0871"},{"key":"2025083110401699000_7.1.e000756.24","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/bcp.13295","article-title":"Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study","volume":"83","author":"Qian","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025083110401699000_7.1.e000756.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-1025-1","article-title":"Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia","volume":"19","author":"Ekbom","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2025083110401699000_7.1.e000756.26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4168\/aair.2019.11.6.795","article-title":"Inhaled corticosteroids in asthma and the risk of pneumonia","volume":"11","author":"Kim","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"2025083110401699000_7.1.e000756.27","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-203175"},{"key":"2025083110401699000_7.1.e000756.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00037-2017"},{"key":"2025083110401699000_7.1.e000756.29","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.10.1247"},{"key":"2025083110401699000_7.1.e000756.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-067OC"},{"key":"2025083110401699000_7.1.e000756.31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/COPD.S190086","article-title":"Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016","volume":"14","author":"Bloom","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083110401699000_7.1.e000756.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009183"},{"key":"2025083110401699000_7.1.e000756.33","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.2147\/COPD.S209273","article-title":"Inhaled corticosteroids and risk of tuberculosis in patients with obstructive lung diseases: a systematic review and meta-analysis of Non-randomized studies","volume":"14","author":"Castellana","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083110401699000_7.1.e000756.34","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2011.160028"},{"key":"2025083110401699000_7.1.e000756.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2009.01589.x"},{"key":"2025083110401699000_7.1.e000756.36","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0202-z"},{"key":"2025083110401699000_7.1.e000756.37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2147\/JAA.S274943","article-title":"Qualitative Study of Practices and Challenges of Stepping Down Asthma Medication in Primary Care Across the UK]]&gt","volume":"13","author":"Bloom","year":"2020","journal-title":"J Asthma Allergy"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2020-000756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:40:23Z","timestamp":1756662023000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2020-000756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,2]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bmjresp-2020-000756"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2020-000756","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}